Celvestrant 250mg Injection

About

Celvestrant 250mg Injection is an advanced endocrine therapy primarily used in the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. It belongs to the class of selective estrogen receptor degraders (SERDs). Unlike aromatase inhibitors that reduce estrogen production, Celvestrant works by binding to and degrading the estrogen receptor (ER) protein within cancer cells. This action effectively downregulates the ER, preventing estrogen from binding and stimulating cancer cell growth. By eliminating the estrogen receptor, Celvestrant offers a distinct mechanism of action that can be effective even in cancers that have become resistant to other endocrine therapies. Administered via intramuscular injection, it ensures sustained systemic exposure, making it a crucial option for postmenopausal women, and sometimes men, with advanced breast cancer who have progressed on prior endocrine therapy.

Uses

• Treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women
• Management of metastatic breast cancer after progression on prior endocrine therapy
• Used in combination with CDK4/6 inhibitors for advanced breast cancer
• Treatment of hormone receptor-positive, HER2-negative advanced breast cancer in men

Directions For Use

This medication is administered intramuscularly by a qualified healthcare professional, typically once a month. Follow your doctor's prescribed schedule.

Benefits

• Degrades estrogen receptors, not just blocks them
• Effective in endocrine-resistant breast cancer
• Targeted action against hormone-sensitive tumors
• Non-oral administration for consistent dosing
• Can be used as monotherapy or in combination
• Improves progression-free survival in advanced settings

Side Effects

• Injection site pain
• Nausea
• Fatigue
• Bone pain
• Hot flashes
• Headache
• Vomiting
• Constipation
• Diarrhea
• Rash
• Elevated liver enzymes
• Peripheral neuropathy

Safety Measures

• Alcohol - No specific contraindication, but general moderation is advised. Excessive alcohol intake may exacerbate fatigue or gastrointestinal side effects.
• Pregnancy - Celvestrant is contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment with Celvestrant as it is unknown if the drug is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with moderate to severe hepatic impairment. Dose adjustments may be necessary, and liver function should be monitored.
• Kidney - No dose adjustment is generally required for mild to moderate renal impairment. Use with caution in severe renal dysfunction.
• Lung - No specific lung concerns are typically associated with Celvestrant; however, general monitoring for any new respiratory symptoms is always prudent.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.